Innovent Biologics, Inc.
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 10 disclosed transactions, Innovent Biologics, Inc. concentrates its licensing activity in Oncology, Metabolic, and Dermatology. Innovent Biologics, Inc. pays a 0.70x discount to market median. Their most common deal structure is License, with an average disclosed value of $318M. Most recent activity: 2026.
Pipeline coverage & gaps
Innovent Biologics, Inc. has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 6 | $16M | $348M |
| Collaboration | 2 | $25M | $233M |
| Option | 2 | $22M | $312M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | immunology & inflammation antibody program | Spero Therapeutics | immunology and inflammation | unknown | — | $1.1B |
| 2022 | Tigulixostat | LG Chem | gout | phase_2 | $10M | $96M |
| 2022 | Tigulixostat | LG Chem | hyperuricemia/gout | phase_3 | $10M | $96M |
| 2021 | orismilast | UNION Therapeutics A/S | psoriasis, atopic dermatitis, hidradenitis suppurativa | phase_2 | $20M | $267M |
| 2021 | Orismilast | Union Therapeutics A/S | hidradenitis suppurativa | phase_2 | $20M | $270M |
| 2021 | Orismilast | UNION therapeutics A/S | hidradenitis suppurativa | phase_2 | $20M | $267M |
| 2021 | GFH925 | GenFleet Therapeutics | KRAS G12C-mutant cancers | phase_1 | $22M | $262M |
| 2021 | GFH925 | GenFleet Therapeutics (Shanghai) Inc. | KRAS G12C-mutant cancers | phase_1 | $22M | $312M |
| 2021 | GFH925 | GenFleet Therapeutics | KRAS G12C-mutant cancers | phase_1 | $22M | $312M |
| 2021 | HQP1351 | Ascentage Pharma Group International | chronic myeloid leukemia (CML), drug-resistant CML | phase_1 | $30M | $195M |
How this is computed
For each Innovent Biologics, Inc. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 0.596, clamped to [0.7, 1.5].